ReviewCNS drugs2011
Pharmacotherapy for smoking cessation: current advances and research topics.
Review in CNS drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 50 citations in OpenAlex.
- Exogenous progesterone for smoking cessation in men and women: a pilot double-blind, placebo-controlled randomized clinical trial.Addiction (Abingdon, England) · 2019Trial
- Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial.American journal of obstetrics and gynecology · 2017Trial
- The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users.Drug and alcohol dependence · 2013Trial
- Impact of Smoking Cessation on Periodontal Tissues.International dental journal · 2022Review
- Association of exercise with smoking-related symptomatology, smoking behavior and impulsivity in men and women.Drug and alcohol dependence · 2018Article
- The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.Drug and alcohol dependence · 2018Article
- The Role of Placental Carbonyl Reducing Enzymes in Biotransformation of Bupropion and 4-methylnitrosamino-1-(3-pyridyl)-1-butanone.Drug metabolism letters · 2017Article
- Pharmacokinetics of Bupropion and Its Pharmacologically Active Metabolites in Pregnancy.Drug metabolism and disposition: the biological fate of chemicals · 2016Article
- The next-generation nicotine vaccine: a novel and potent hybrid nanoparticle-based nicotine vaccine.Biomaterials · 2016Article
- Association between duration of use of pharmacotherapy and smoking cessation: findings from a national survey.BMJ open · 2015Article
- The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.Psychopharmacology · 2014Article
- Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice.British journal of clinical pharmacology · 2014Review
- Bumps along the translational pathway: anticipating uptake of tailored smoking cessation treatment.Personalized medicine · 2013Article
- Review
- Current and emerging pharmacotherapeutic options for smoking cessation.Substance abuse : research and treatment · 2013Article
- Nicotine vaccines to treat tobacco dependence.Human vaccines & immunotherapeutics · 2013Review
- Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.The Journal of pharmacology and experimental therapeutics · 2012Article
- Best approaches in the battle against Globesity? Learning lessons from our experience tackling HIV-AIDS and tobacco smoking.JRSM short reports · 2012Article
- Nicotine as a potential neuroprotective agent for Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2012Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Promoting smoking cessation is among the key medical interventions aimed at reducing worldwide morbidity and mortality in this century. Both behavioural counselling and pharmacotherapy have been shown to significantly increase long-term abstinence rates, and combining the two treatment modalities is recommended. This article provides an update on pharmacotherapy for smoking cessation in the general population. Current first-line agents used to support quit attempts are nicotine replacement therapy (NRT), bupropion and varenicline. Research suggests that abstinence rates can be increased by combining different forms of NRT or simultaneously administering NRT and non-nicotine medications. New treatments targeting the nicotinic acetylcholine receptor as well as other pathophysiological pathways involved in nicotine addiction are being developed, with nicotine vaccines now being tested in phase III clinical trials. Among the numerous research topics currently addressed, pharmacogenetics and tailoring therapy to specific groups of smokers look most promising. However, substantial progress is unlikely to be made unless social gradients impeding effective treatment of all smokers are overcome. In addition, public smoking bans and reimbursement of medication costs are crucial in reducing the future burden of disease caused by smoking on a global level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.